B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 0.4915 NOK -1.11% Market Closed
Market Cap: 19.2m NOK

Net Margin
Bergenbio ASA

-1 990.4%
Current
-42 963%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 990.4%
=
Net Income
-107.6m
/
Revenue
5.4m

Net Margin Across Competitors

No Stocks Found

Bergenbio ASA
Glance View

Market Cap
19.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
2.1597 NOK
Undervaluation 77%
Intrinsic Value
Price
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 990.4%
=
Net Income
-107.6m
/
Revenue
5.4m
What is the Net Margin of Bergenbio ASA?

Based on Bergenbio ASA's most recent financial statements, the company has Net Margin of -1 990.4%.

Back to Top